These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 19096817)

  • 21. Long-term cognitive effects of glucocorticoid excess in Cushing's syndrome.
    Forget H; Lacroix A; Bourdeau I; Cohen H
    Psychoneuroendocrinology; 2016 Mar; 65():26-33. PubMed ID: 26708069
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Familial/sporadic glucocorticoid resistance syndrome and hypertension.
    Kino T; Vottero A; Charmandari E; Chrousos GP
    Ann N Y Acad Sci; 2002 Sep; 970():101-11. PubMed ID: 12381545
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pathophysiology of Glucocorticoid Signaling.
    Vitellius G; Trabado S; Bouligand J; Delemer B; Lombès M
    Ann Endocrinol (Paris); 2018 Jun; 79(3):98-106. PubMed ID: 29685454
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Metabolic comorbidities in Cushing's syndrome.
    Ferraù F; Korbonits M
    Eur J Endocrinol; 2015 Oct; 173(4):M133-57. PubMed ID: 26060052
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Studies on high affinity binding of mineralo- and glucocorticoids in rabbit aorta cytosol.
    Kornel L; Kanamarlapudi N; Travers T; Taff DJ; Patel N; Chen C; Baum RM; Raynor WJ
    J Steroid Biochem; 1982 Feb; 16(2):245-64. PubMed ID: 6281578
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cortisol--cause and cure for metabolic syndrome?
    Walker BR
    Diabet Med; 2006 Dec; 23(12):1281-8. PubMed ID: 17116176
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pathophysiology of dyslipidemia in Cushing's syndrome.
    Arnaldi G; Scandali VM; Trementino L; Cardinaletti M; Appolloni G; Boscaro M
    Neuroendocrinology; 2010; 92 Suppl 1():86-90. PubMed ID: 20829625
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Expression of selected angiogenesis-related small microRNAs in patients with abnormally increased secretion of glucocorticoids.
    Kawa MP; Sobuś A; Litwińska Z; Osowicz-Korolonek L; Cymbaluk-Płoska A; Stecewicz I; Zagrodnik E; Romanowska H; Walczak M; Syrenicz A; Machaliński B
    Endokrynol Pol; 2019; 70(6):489-495. PubMed ID: 31909455
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Hypertension and Cardiovascular Mortality in Patients with Cushing Syndrome.
    Nieman LK
    Endocrinol Metab Clin North Am; 2019 Dec; 48(4):717-725. PubMed ID: 31655772
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Metabolic Alterations and Cardiovascular Outcomes of Cortisol Excess.
    Pivonello R; De Martino MC; Iacuaniello D; Simeoli C; Muscogiuri G; Carlomagno F; De Leo M; Cozzolino A; Colao A
    Front Horm Res; 2016; 46():54-65. PubMed ID: 27212264
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Secondary diabetes associated with principal endocrinopathies: the impact of new treatment modalities.
    Resmini E; Minuto F; Colao A; Ferone D
    Acta Diabetol; 2009 Jun; 46(2):85-95. PubMed ID: 19322513
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cortisol Secretion, Sensitivity, and Activity Are Associated With Hypertension in Postmenopausal Eucortisolemic Women.
    Chiodini I; Gaudio A; Eller-Vainicher C; Morelli V; Aresta C; Zhukouskaya VV; Merlotti D; Orsi E; Barbieri AM; Fustinoni S; Polledri E; Gennari L; Falchetti A; Carnevale V; Persani L; Scillitani A
    J Clin Endocrinol Metab; 2019 Oct; 104(10):4441-4448. PubMed ID: 31112276
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Treatment of iatrogenic Cushing syndrome: questions of glucocorticoid withdrawal].
    Igaz P; Rácz K; Tóth M; Gláz E; Tulassay Z
    Orv Hetil; 2007 Feb; 148(5):195-202. PubMed ID: 17344139
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Obesity and corticosteroids: 11beta-hydroxysteroid type 1 as a cause and therapeutic target in metabolic disease.
    Morton NM
    Mol Cell Endocrinol; 2010 Mar; 316(2):154-64. PubMed ID: 19804814
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Adverse effects of glucocorticoids: coagulopathy.
    Coelho MC; Santos CV; Vieira Neto L; Gadelha MR
    Eur J Endocrinol; 2015 Oct; 173(4):M11-21. PubMed ID: 25971647
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Glucocorticoid receptors and Cushing's disease.
    Lamberts SW
    Mol Cell Endocrinol; 2002 Nov; 197(1-2):69-72. PubMed ID: 12431798
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tissue-specific glucocorticoid reactivating enzyme, 11 beta-hydroxysteroid dehydrogenase type 1 (11 beta-HSD1)--a promising drug target for the treatment of metabolic syndrome.
    Masuzaki H; Flier JS
    Curr Drug Targets Immune Endocr Metabol Disord; 2003 Dec; 3(4):255-62. PubMed ID: 14683456
    [TBL] [Abstract][Full Text] [Related]  

  • 38. How do glucocorticoids cause hypertension: role of nitric oxide deficiency, oxidative stress, and eicosanoids.
    Ong SL; Whitworth JA
    Endocrinol Metab Clin North Am; 2011 Jun; 40(2):393-407, ix. PubMed ID: 21565674
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Adrenal incidentaloma: effects on bone metabolism.
    Francucci CM; Caudarella R; Rilli S; Fiscaletti P; Ceccoli L; Boscaro M
    J Endocrinol Invest; 2008 Jul; 31(7 Suppl):48-52. PubMed ID: 18791352
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Glucocorticoid-induced hypertension.
    Goodwin JE; Geller DS
    Pediatr Nephrol; 2012 Jul; 27(7):1059-66. PubMed ID: 21744056
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.